Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery - 1 May 2010

Wang Chun-meng, Shi Ying-qiang, Fu Hong, Zhao Guang-fa, Zhou Ye, Du Chun-yan, Ye Yan-wei

Abstract excerpt

OBJECTIVE: To characterize oncogenic KIT signaling mechanisms in gastrointestinal stromal tumor(GIST), and to determine which signaling pathway might be of potential relevance to imatinib acquired resistance. METHODS: The mutations of KIT and PDGFRa gene were evaluated and KIT downstream signaling profiles were evaluated in 8 specimen from 5 GIST patients who were evaluated treated between 2003 and 2008 in our...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Share to Signal Transduction

Source

Identifiers

PMID: 20499309

Genes

KIT
MTOR
PCNA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor].PMID 20499309Read ↗

Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors.Semantic proximity Read ↗

[Molecular mechanisms of primary and secondary resistance, molecular-genetic features and characteristics of KIT/PDGFRA non-mutated GISTs].Semantic proximity Read ↗

[Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].Semantic proximity Read ↗

KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.Semantic proximity Read ↗

RAF1 facilitates KIT signaling and serves as a potential treatment target for gastrointestinal stromal tumor.Semantic proximity Read ↗

[Molecular mechanism of gastrointestinal stromal tumors and progress in drug research].Semantic proximity Read ↗

[Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].Semantic proximity Read ↗

KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST.Semantic proximity Read ↗

Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review).Semantic proximity Read ↗

Secondary mutations in the kinase domain of the <i> KIT</i> gene are predominant in imatinib‐resistant gastrointestinal stromal tumorSemantic proximity Read ↗

New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs.Semantic proximity Read ↗

[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.